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Rheumatoid arthritis is the most prevalent autoimmune disease. Rheumatoid arthritis (RA) has 
no cure, and the direct cause of the disease is still unknown. The two leading hypotheses 
concerning its etiology are based on the effects of HLA-DRB1 gene expression, and cigarette 
smoke. Conjunctively, the use of vaping devices amongst adolescents has increased significantly 
since introduced in 2007. There is no long-term data on the effects of e-vapor and its aerosols on 
bodily health. Cigarette smoke is the most noteworthy environmental factor contributing to RA 
therefore the question is raised as to whether or not vaping relates to rheumatoid arthritis 
susceptibility. This extended literature review focused on the current knowledge of RA, as well 
as cigarette smoke and its role in rheumatoid arthritis pathogenicity. An experimental proposal is 
also described which analyzes the effects of e-vapor on collagen induced arthritis mouse models. 
HLA-DRB1 gene expression, autoantibody proliferation and rheumatoid arthritis symptomology 
were investigated in acute and chronic RA mouse models. Ideally, these experiments would 




Keywords: Rheumatoid arthritis, environmental factors, vapor, cigarette smoke, HLA-DRB1 
  
 vi 
TABLE OF CONTENTS 
List of abbreviations…………………………………………………………………………...viii 
Introduction……………………………………………………………………………….…….1 
Methodology………………………………………………………………………………….…5 
REVIEW OF THE LITERATURE 
Chapter 1: The Immune System…………………………………………………….…6 
  Antibodies…………………………………………………………………….….6 
  Antibody Structure…………………………………………………………….…9 
  Complement……………………………………………………………………..10 
  Cytokines………………………………………………………………………..12 
  Autoantibodies......................................................................................................13 
Chapter 2: Rheumatoid Arthritis..................................................................................15 
  Rheumatoid Arthritis............................................................................................15 
Etiology................................................................................................................16 
  Gene Expression...................................................................................................19 
  HLA Genes...........................................................................................................21 
Chapter 3: Current Treatments....................................................................................23 
  Treatment Course of Action.................................................................................23 
Glucocorticoids.....................................................................................................25 
Methotrexate.........................................................................................................26 
Tumor Necrosis Factor Alpha Inhibitors..............................................................26 
IL-6 Inhibitors......................................................................................................27 
JAK-Inhibitors......................................................................................................28 
Chapter 4: Cigarette and E-Vapor...............................................................................30 
  Cigarette Smoke...................................................................................................30 
  Cigarette Smoke Immune Impact.........................................................................31 
  Vaping and E-Vapor Components........................................................................33 
  E-Vapor and Adolescents.....................................................................................36 
  E-Vapor Effects on the Body...............................................................................36 
Chapter 5: Laboratory Research Proposal..................................................................40 
  Specific Aims.......................................................................................................40 
  Preparing Arthritic Mouse Models.......................................................................41 
  CRISPER-CAS9...................................................................................................41 
Aim I.....................................................................................................................42 
  Aim II...................................................................................................................44 
  Aim III..................................................................................................................45 
  Experimental Pitfalls and Future Aims................................................................46 





LIST OF ABBREVIATIONS 
 
ACPA Anti-citrullinated Protein Antibody 
APC Antigen Presenting Cell 
CDC Center for Disease Control 
CFA Complete Freunds Adjuvant 
CS Cigarette Smoke 
csDMARD Conventional Synthetic Disease-Modifying Anti Rheumatic Drug 
DMARD Disease-Modifying Anti Rheumatic Drug 
EVALI E-cigarette/vaping product use-associated lung injury 
EURLAR European League Against Rheumatism, 
GC Glucocorticoids 
HLA Human Leukocyte Antigen 
IFA Incomplete Freud’s Adjuvant 
Ig Immunoglobin 
IL Interleukin 
JAK Januse Kinase 
JAKi Januse Kinase Inhibitor 
KO Knock Out (relates to mouse models) 
MHC Major Histocompatibility Complex 
MP Metacarpophalangeal Joints 
MTX Methotrexate 
NSAIDs Non-Steroidal Anti-Inflammatory Drugs 
OS Oxidative Stress 
PIP Proximal Interphalangeal Joint 
PG Propylene Glycol 
RA Rheumatoid Arthritis 
RF Rheumatoid Factor 
SE Shared epitope 
STAT Signal Transducer and Activator of Transcription 
TC Traditional Cigarettes 
Tc T-cell 
Th Helper T-cell 
THC Tetrahydrocannabinol  
TNF Tumor Necrosis Factor 
TNFi  Tumor Necrosis Factor Inhibitor 
Treg Regulatory T cell 
tsDMARDs Targeted Synthetic Disease-Modifying Anti Rheumatic Drug 
VG Vegetable Glycerin 
WBC White Blood Cell 
 1 
INTRODUCTION 
Rheumatoid arthritis is a chronic, inflammatory autoimmune disease which develops 
within the joints and can lead to life-threatening complications throughout the body. Currently, 
as with many autoimmune diseases, there is no cure for rheumatoid arthritis (RA). Pain 
management and immunosuppressive pharmaceuticals are the only options to which the over 23 
million RA patients can turn.1 Approximately one percent of the adult population of the world 
experiences RA which makes it the most common form of rheumatic diseases.1 This equates to 
approximately 78,000,000 individuals. RA has no known cause, but current hypotheses note the 
potential roles of gene expression coinciding with environmental factors such as cigarette 
smoking (CS), obesity, age and gender.2 
Rheumatoid arthritis begins its path of destruction by attacking the synovium, then 
disseminate into the surrounding joints and bone causing massive tissue degradation.3 It first 
attacks the synovium- a flexible sac of fluid surrounding joints. Originating within small joints, 
RA then spreads to larger joints, and, in severe cases, certain organs.1,2 Some joints that are 
affected as this disease progresses include the wrists, elbows, and knees eventually leading to 
effects on organs such as the skin, eyes, heart, blood vessels, kidney, spleen and lungs.2,3 Fluid 
build-up, inflammation, deterioration, pain, and loss of joint mobility, are common symptoms of 
RA.2 
There are several forms of arthritis, therefore it is critical to note that RA is different from 
alternative forms of arthritis such as osteoarthritis because it affects the proximal interphalangeal 
(PIP) and metacarpophalangeal (MP) joints, rather than the distal joints of the hands and feet.2 
This inflammation and destruction of the proximal joints leads to deformities such as the swan 
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neck and boutonniere, as shown in Figure 1 
which lead to a severe decrease in quality of 
life and loss of mobility given their 
characteristic misshapenness, swelling and 
degradation.24   
Biologically, it is thought that 
rheumatoid arthritis is triggered by changes 
in the innate and adaptive immune systems 
which leads to autoantibodies such as 
Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPAs) being produced 
from B-cells. These autoantibodies are then allowed to circulate through the body thus eliciting a 
self-reactive response by cytotoxic T-cells (TC).
2,5 These autoantibodies begin to attack the 
synovial membrane due to an error in differentiating self from foreign antigens which leads to 
inflammation and fluid build-up causing joint and cartilage erosion common with RA.5 A 
definitive causation of RA (prior to its measurable effects on the body) is still unknown, but it is 
thought to be affected by both an increase in genetic susceptibility and environmental factors, 
particularly cigarette smoking.2,4  
Cigarette smoking, as mentioned previously, is the number one environmental contributor 
to rheumatoid arthritis.6 Current data has established there is a strong correlation between CS 
exposure and RA development; specifically via the HLA-DRB1 gene responsible for 
autoantibodies RF and ACPA production.6 CS is associated with HLA-DRB1 activation, and 
therefore relates to the upregulation of autoantibody production.6 Notably, not all individuals 
who smoke traditional cigarettes experience an increase in autoantibody production- this is 
Figure 1: Degradation of RA joint. Depicts the notable 
deformations such as swan neck and boutonniere in the 
fingers caused by RA.24 
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thought to be due to the duration and intensity with which the individual smoked, though 
duration is most critical for RA onset, rather than intensity alone. 6 Regardless of autoantibody 
proliferation rates, however, CS is associated with an increased risk of RA development.6 Many 
studies have indicate the environmental and genetic impacts of CS on RA, however, few have 
concerned the effects of e-vapor. 
E-vapor, otherwise known as vaping, is a fairly new form of e-cigarette popular amongst 
adolescents and young adults. Over 16 million adolescents vape within the United States since 
the beginning of 2020 which is a drastic increase from 2018 statistics listing 1.3 million 
adolescents actively vaping.7  This robust market offers many options to consumers in order to 
vape based on their individual preferences. For instance, vaping machinery varies greatly in 
design and purpose- including but not limited to ohm power, heat capacity of the coils, density of 
vapor expelled, flavoring, and the sizes of the modules. Due to the large variability amongst the 
types of vape available, few studies have been conduction on its health implications, either 
negative or positive. With the large array of vape modules on the market, standardizing 
experimentation has posed as an obstacle within laboratory settings. The Center for Disease 
Control states that smokers who utilize vaping as a way to quit smoking in the traditional 
manner, due to the hypothetical decreased levels of carcinogens in vaping products.8 However, 
opposing studies hypothesize that vaping is just as severe to one’s health as CS, if not more.6 
This stark contrast of data epitomizes the current understanding of vaping. Ultimately, there is 
not scientific, nor popular opinion, consensus on the effects of vaping. In fact, most of the 
literature available on the subject are based on the legislation surrounding how vape companies 
target minors via advertising, as well as public perception of vape.7,8 The studies that have been 
released concerning vape and human health, indicate vaping leads to high rates of reactive 
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oxygen species in the body, as well as negative repercussions on lung health.9,10 The long-term 
effects of vape have yet to be uncovered. Therefore, there is an immense need for studies focused 
on the complexity of e-vapor. Since vaping is tremendously popular amongst youth and young 
adults, the need has quickly arisen to study longitudinal effects of vaping. Given the 
contributions to RA CS has, there may prove to be a strong correlation between vape and the 
onset of rheumatoid arthritis later in life. Studies must be pursued in order to ascertain the 
possible effects of vaping on RA to save a future generation from what may be a fairly avoidable 




 Since the data concerning the subject matter of Rheumatoid Arthritis and cigarette 
smoking is vast, but the information pertaining to RA and e-vapor is sparse, the most effective 
route of methodology is an extensive review of the literature. Databases such as PubMed, 
EBSCO, Academic Search Complete and others were utilized in order to closely study the 
research of those who have paved the way in this content area. Furthermore, a proposed 
laboratory experiment concerning the effects of e-vapor on rheumatoid arthritis mouse models is 
disclosed beginning on page 40. It is critical to note that though this experiment is theoretical, it 
is believed to be an effective summation and comparison of the current data on cigarette smoke, 
e-vapor and their effects on the potential induction of rheumatoid arthritis and its pathogenicity, 




REVIEW OF THE LITERATURE 
The Immune System 
 The immune system is a highly efficient and complex network present throughout the 
human body. This elaborate system of checks and balances for the overall health of the body is 
made possible by the intricate relationships, chain reactions and signaling abilities between 
millions of immune cells.9 Rheumatoid arthritis is characterized by the malfunction of said 
immune cells.10 RA occurs when there is a change from immune cells being protectors of 
nonpathogenic tissue to agitators against the body, in particular cells that make up the synovial 
membranes surrounding joints.10 This phenomena is thought to occur due to autoantibody B 
lymphocytes in conjunction with T-cells (T-lymphocytes) becoming proinflammatory effector 
cells instead of regulatory T-cells (Treg) thus causing a chain reaction response in the immune 
system.10 Treg cells function to suppress the responses of other T-cell subsets (such as 
proinflammatory TH1 and TH2 cells), antigen presenting cells and B-lymphocytes.
11 These 
autoreactive (self-attacking) T-cells partner with autoantibodies released from B-cells thus 
eliciting a destructive immune response leading to joint degradation, inflammation and the 
eventual replacement of healthy flexible tissue with dense fibrous tissue.10 Before the RA 
pathogenicity can be fully understood, however, one must comprehend the key players in a 
healthy immune system. 
Antibodies 
 Antibodies, otherwise known as immunoglobulins (Ig), are the linchpin to the immune 
system. Without these proteins, the body would be largely unable to recognize foreign pathogens 
such as bacteria, viruses and foreign entities.11 There are two broad types of lymphocytes 
immune cells, T-lymphocytes, also called T-cells, and B-lymphocytes known as B-cells.11 B-
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cells generate billions of unique forms of themselves and antibodies that correlate with their 
characteristics in order to ward of infection.11 This diversity is crucial to the adaptive immune 
system which learns to identify specific pathogens by experiencing multiple exposures to said 
molecules, thus creating memory within the immune system.  
There are five broad categories of immunoglobulins, IgA, IgD, IgE, IgG and IgM.11 Each 
type of Ig correlates with one specific type of antigen-binding site.11 IgM is known for its role on 
naïve B-cells which is further explained in the following paragraphs.11 IgA is common within the 
mucosal lining and activates mucosal tissue responses to pathogens.12 IgE activate granulocytes 
(such as mast cells, eosinophils and basophils) and primarily respond to allergens or parasites 
within the body.12 IgD is not well understood but potentially assists in process of B cell 
maturation.12 IgG is famous for its role in binding to Fc𝛾 receptors on T cells which are then 
activated to respond and assist mature B-cells (also known as effector or plasma cells).11 IgG is 
an opsonin which is a biochemical marker that signals for phagocytosis.11 Its role is critical to the 
negative effects of RA, but it may also play a role in the prevention or treatment of rheumatoid 
arthritis.12 IgG is the most noteworthy Ig for RA, and while the other antibodies are significant 
within the body they have shown little direct correlation with RA for the purpose of the 
discussion on hand. 
Antibodies have exclusive relationships with antigens. A specific antibody will only bind 
to a specific antigen.11 Antigens, or molecules that cause an immune response, can range 
anywhere from a sliver of wood in an index finger to cancerous cells, and nearly anything in 
between. In ideal situations, the immune system is able to detect, label and bind with each 
specific enemy it faces in order to quickly and effectively terminate the threat. 
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Each B-cell generates an antibody with one type of receptor for a specific antigen.11 Prior 
to releasing an antibody army against pathogens though, each naïve B-cell within the bone 
marrow must undergo a maturation process so it learns to recognize foreign invaders from 
healthy, nonpathogenic, “self,” cells.11 IgMs are presented on the B-cell surface as a way for the 
immature B-cell to identify a new threat from a variety of cells it faces and then allows it to 
signal for specific immune responses.11 Upon binding with a foreign substance, as a B-cell 
generates its first antibodies aside from IgM, the antibodies are inserted into the plasma 
membrane.11 With 105 receptors on a B-cell, the maturing B-cell with its respective antibodies is 
able to quickly signal through intracellular pathways when an antigen binds to any of its antigen-
binding sites.11 Once an antigen is bound to the immature naïve B-cell, the B-cell multiplies and 
differentiates into an antibody-secreting effector cell with the assistance of a helper T-cell (Th) in 
Figure 2. 11  
Figure 2: Activation and Class-Switching of B-cells. This indicates the complex relationship 
antigen presenting cells, T-helper cells, active T cells, and B-cells have with one another in 
order to elicit a healthy immune response.12 
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Specific cytokines are then released in response to the B-cell/T-cell partnership.11 Once 
the B-cell has matured, the antibodies it makes are secreted rather than bound to the plasma 
membrane since the B-cell has learned to recognize pathogen from self-cells and is now 
considered an active plasma cell.11 If a B-cell is unable to differentiate between self and 
pathogenic material, it is destroyed or deactivated unless it evades those actions.11 
Antibody Structure 
B-cells generate antibodies.11 Antibodies are able to bind to antigens due to their unique 
molecular structure and binding regions.11 Each antibody is a “Y”-shape consisting of two heavy 
polypeptide chains and two light chains, as shown in Figure 3.11  
The heavy chain gives an 
antibody a name- one of any of the 
five classes mentioned prior (IgA, 
IgD, IgE etc.).11 The hinge regions 
between the “Y” arms and the tail (Fc 
region) of the “Y” are uniquely 
capable of creating more or less space 
between the antigen binding sites in 
order to optimize binding affinity.11 
The antigen binding sites are at either 
end of the “Y” arms and between the 
N-terminal regions of one light chain 
and one heavy chain.11 Although there 
is a pair(s) of antigen binding sites, it 
Figure 3: Antibody Structure. Antibodies consist of two light 
chain and two heavy chain regions.12 Additionally, the ends 
of the antibody where the antigen binding site is located are 
known as variable regions while the tail of the antibody is 
the constant region.11 
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is necessary to note this does not change the one-to-one binding relationship of an antibody to a 
specific antigen.11 The stem of the “Y” is the portion of an antibody other immune cells, like Th 
cells, read in order to determine how they should respond to the antigen the antibody is 
holding.11 
Complement 
 The immune system functions in two broad but intertwined categories: innate and 
adaptive.12 The complement system is most often considered a product of the innate immune 
system.12 It is a way for antibodies, a component of the adaptive immune system, and phagocytes 
such as macrophages, monocytes and granulocytes to enhance their collaboration.12 This 
partnership allows them to rid microbes and damaged cells from the body.12 Within this process 
four major functions are executed: lysis of infectious organisms, activation of inflammation, 
opsonization and immune clearance.12 Lysis and apoptosis is often achieved by phagocytes, short 
lived neutrophils, and longer living monocytes or macrophages which “digest” cell matter.13 The 
act of degradation via any of these cells, depending on the signals received, can quickly lead to 
inflammation.13 Inflammation by definition is the accumulation of fluid and cell matter caused 
by blood vessel dilation.13 This is a positive result of the body attempting to fight off an attack, 
thus signaling for an influx in white blood cells however, when inflammation is chronic it leads 
to serious repercussions— such is the case in RA.12 Opsonization is a biochemical marker which 
is brought on most frequently by IgG on plasma cells and indicates the need for antigen 
destruction by phagocytosis.12 
 In order for cells to recognize the need for phagocytosis, there must be T-cell activation, 
which is triggered by antigen presentation.14 The adaptive and innate immune systems work via 
B-cells and other antigen presenting cells (APCs) such as macrophages and dendritic cells (DC), 
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respectively expressing class II MHC molecules while all nucleated cells express MHC class I.14 
MHC I signifies two main roles. Firstly, it exclusively signals for cytotoxic T-cells that kill 
threats on contact. Secondly, MHCI is the indication to immune cells that the cell it is on is 
“self,” therefore cells that have MHCI on their surfaces are not destroyed by natural killers 
(NKs).13 Major histocompatibility complex (MHC II) is required for T cells to read an antigen. 
This differs from B cells which can bind directly to a pathogen, in that rather than displaying a 
whole antigen on its surface, MHCII display small peptides of an antigen on the cell surface for 
T-cell receptors.15 MHC II recruits helper T-cells which positively assist B-cells by aiding in 
their release of antibodies.14,15 In autoimmune diseases where MHC II malfunctions, only MHC I 
is able to signal which leads to extensive cellular death brought on by the excessive presence of 
cytotoxic CD8+ T-cells.15  
As opposed to cytotoxic T-cells, when helper T-cells are activated they divide and secrete 
cytokines that can regulate and assist in the immune response.14 They are able to signal for white 
blood cells to respond to the infected area, thus increasing symptoms of an immune response, but 
not exclusively calling for immediate phagocytosis of threatening cells.16 Research has indicated 
that helper T-cells as well as effector cytotoxic (TC) act within the synovium of joints of RA 
patients.13 In the synovium of RA patients, Th and TC cells signal for increased cellular response 
from immune cells, such as macrophages, B-cells and cytotoxic T cells, and destroy healthy cells 
perceived to be pathogenic, respectively.13 Once cytotoxic T-cells are activated, they are effector 
cells which target and kill any other cell that has the same pathogen within it.15 
Normally, the body screens for self-reactive T-cells during their development in the 
thymus.15 However, self-reactive T-cells either by-pass checkpoints during their maturation 
process or mutate later to become self-reactive.15 Self-reactive T-cells are able to independently 
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bind strongly to self MHC complexes rather than requiring the assistance of CD4/8 co-
effectors.15 Since the T-cell does not require a co-effector, it is able to bind to any cell that is 
displaying self MHC, rather than self MHC that is simultaneously displaying a foreign 
pathogen.15 This upheaval in the T-cell binding affinity leads to a heightened immune response 
due to the increase in apoptosis.15 Chronic inflammation caused by the cytokines released, as 
well as the flood of white blood cells signaled to the area due to the cytotoxic cell destruction, 
leads to the symptoms of RA.13 A clear route from acute to chronic inflammation has not yet 
been discovered, but chronic inflammation is associated with an increase in macrophages and 
lymphocytes to the site of infection.17 Long-term inflammation signals the body to have 
increased blood flow/vasodilation which naturally increases the migration of white blood cells to 
the area where antibodies are signaling for a response. This response becomes a vicious cycle 
that perpetuates the devastation of RA.18 
Healthy immune response ordinarily begins with neutrophils because they are able to 
signal for inflammatory response, but these cells quickly die to prevent prolonged signaling.18 In 
rheumatoid arthritis, due to persistent inflammatory signals, longer living white blood cells 
(WBC) such as macrophages and lymphocytes have to respond to the inflammation and cell 
deaths since the neutrophil population becomes depleted.18 The normally healthy process of a 
quick and efficient response to pathogens instead leads to long-term inflammation and 
degradation due to the prolonged presence of macrophages, lymphocytes and the cells they 
signal (B and T-cells).18 In turn, degradation leads to the replacement of healthy tissue around 
the bones to be replaced with much stiffer connective tissue built by fibroblasts since the 
synovium is degrade to such large degrees.18 
Cytokines 
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Cytokines are signaling molecules that act as regulators of temperature, inflammation, 
neutrophil mobilization and many other responses in the immune system.16 There are 
approximately 50 types of cytokines known in the human body, each with its role and regulatory 
ability.16 Early RA is thought to be affected by eleven different cytokines, including cytokine 
tumor necrosis factor alpha (TNFɑ) and interleukin-6 (IL-6), although this data is tentative.16 
TNF and IL-6 are both pro-inflammatory cytokines which by definition increase inflammatory 
response and increase osteoclast differentiation in the joints, specifically.16 Together, these two 
cytokines simultaneously increase pressure within the synovium around joints and increase the 
population of cells that degrade bone.16 Also key to rheumatoid arthritis are T-helper 17 (Th17) 
cells.19 Th17 cells produce cytokines interleukin-17A (IL-17A), IL-17F and IL-22.19 IL-17A and 
IL-17F are known to recruit and activate neutrophils and stimulate other cells to produce 
inflammatory cytokines such as IL-6.19 This combination of Th17 cell subtypes is thought to be a 
cause to the chronic inflammation within the joints of RA patients.19 
Autoantibodies 
 Autoreactive T-cells interact with autoantibodies released from self-reactive B-cells.12 
Autoantibodies are antibodies that have become self-reacting, rather than self-protecting.20 
Ordinarily, autoantibodies are only found in minute amounts as IgM molecules, however, large 
amounts of autoantibodies cause detriment to the body.20 Autoantibodies that undergo mutations 
are no longer non-antigenic, therefore they trigger defensive immune reactions against self-
cells.21 The chemical trigger which leads to the change from healthy antibodies from B-cells to 
autoantibodies is largely undiscovered. Alberts, Johnson and team showed great promise in their 
recent study indicating how Rho, a small GTPase, may signal for negative changes to B and T-
cell development, activation proliferation differentiation and migration.14 Regardless, 
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mutation(s) within IgM antibodies become IgG autoantibodies- known to be more widespread 
and have specific adhesion properties compared to healthy IgM which do not have specific 
adhesion properties.21 This change thus leads to a broader ability to inaccurately bind to self-cells 
and elicit an unnatural and detrimental immune response. ACPA and RF are two autoantibodies 
commonly present in preclinical disease onset.3 As mentioned within the Biomarkers portion of 
this discussion, these autoantibodies have been utilized as early indicators that RA may develop, 
and its severity may be predicted.2 Also, the increased production of these autoantibodies is 
strongly correlated with the environmental factor of cigarette smoking.1 Therefore, recent 
literature has begun to explore the possible genetic pathways affected by cigarette smoke that 





Rheumatoid arthritis is a chronic, inflammatory autoimmune disease which develops 
within the joints and can lead to life-threatening complications throughout the body. Currently, 
as with many autoimmune diseases, there is no cure for rheumatoid arthritis (RA). Pain 
management and immunosuppressive pharmaceuticals are the only options to which the over 23 
million people affected by RA can turn.1 Approximately two percent of the adult population of 
the world experiences RA which makes it the most common form of rheumatic diseases.1 RA has 
no known cause, but current hypotheses note the potential roles of gene expression coinciding 
with environmental factors such as cigarette smoking (CS), obesity, age and gender.2 
Rheumatoid arthritis begins its path of destruction by attacking the synovium, then creeps 
its way into the surrounding joints and bone causing massive tissue degradation.3 It first attacks 
the synovium- a flexible sac of fluid surrounding joints. Originating within small joints, RA then 
spreads to larger joints, and, in severe cases, certain organs.1,2 Some joints that are affected as 
this disease progresses include the wrists, elbows, and knees eventually leading to effects on 
organs such as the skin, eyes, heart, blood vessels, kidney, spleen and lungs.2,3 Fluid build-up, 
inflammation, deterioration, pain, and loss of joint mobility, are common symptoms of RA.2 
There are several forms of arthritis, therefore it is critical to note that RA is different from 
alternative forms of arthritis such as osteoarthritis because it affects the proximal interphalangeal 
(PIP) and metacarpophalangeal (MP) joints, rather than the distal joints of the hands and feet.2 
This inflammation and destruction of the proximal joints leads to deformities such as the swan 
neck and boutonniere, as shown in Figure 4  which lead to a severe decrease in quality of life and 
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loss of mobility given their characteristic misshapenness, swelling and degradation.2 
 
Biologically, it is thought that rheumatoid arthritis is triggered by changes in the innate 
and adaptive immune systems which leads to autoantibodies such as Rheumatoid Factor (RF) 
and Anti-Citrullinated Protein Antibodies (ACPAs) being produced from B-cells. These 
autoantibodies are then allowed to circulate through the body thus eliciting a self-reactive 
response by cytotoxic T-cells (TC).
2,5 These autoantibodies begin to attack the synovial 
membrane due to an error in differentiating self from foreign antigens which leads to 
inflammation and fluid build-up causing joint and cartilage erosion common with RA.5 A 
definitive causation of RA (prior to its measurable effects on the body) is still unknown, but it is 
thought to be affected by both an increase in genetic susceptibility and environmental factors, 
particularly cigarette smoking.2,4  
Etiology 
 The etiology of rheumatoid arthritis is still unknown, however, there are several factors 
that lead to an increased risk of developing RA. Gender, age, obesity, genetic susceptibility, 
environmental factors and biomarkers all can indicate vulnerability to developing this 
autoimmune disease.1 Research has unanimously concluded that the most vulnerable population 
by far is middle-age women— notably, there seems to be few differences in susceptibility when 
the ethnicities of middle-age women are considered.1 
Boutonniere deformity 
 




Figure 4: Boutonniere and swan neck deformities 
common to RA joint degradation2 
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Beyond one’s sex increasing the risk of RA, there are many studies which support the 
potential for familial inheritance to play a role in the susceptibility of a patient to develop 
rheumatoid arthritis.1 Several genes have been identified as possible ties to RA. Major 
Histocompatibility Complex (MHC) genes, which consist of three separate classes of “HLA-X,” 
are thought to be one of the genomic indicators of RA.1 The HLA-DRB1 gene is one of the 
Human Leukocyte Antigen (HLA) gene complexes whose role is to encode for MHC class II 
antigen-presenting molecules.6 MHC molecules, as described in the Immune System section, are 
antigen-presenting molecules responsible for the relationship immune cells have with peptides 
on the outside of antigen presenting cells (APCs).5 If the protein made by HLA-DRB1 holds a 
peptide that the immune cells do not recognize it, they signal for an inflammatory response in 
order to rid the body of the foreign antigen.7 This cascade of events beginning from the MHC 
gene is therefore critical in anti-citrullinated protein antibody (ACPA) positive patients because 
these autoantibodies are unrecognized by the body and trigger an inflammatory immune 
response.1 The role of gene expression in RA pathology is described further in the section Gene 
Expression for RA. 
Biomarkers are measurable indicators of normal healthy processes or pathogenic 
operations that can be used to detect rheumatoid arthritis.7 Two biomarkers, anti-citrullinated 
protein antibodies (ACPAs), as mentioned previously, and rheumatoid factor (RF) play a 
significant role in determining the probability of developing RA and its severity.7 Over 75% of 
RA patients express these biomarkers, hence making them a lead indication for RA.1 High levels 
of RF, in particular, indicate the risk for developing aggressive rheumatoid arthritis that greatly 
limits joint functionality.7 ACPAs develop as ACPA-positive or negative, the positive indicating 
a patient may develop more bone erosion and severe disease progression in comparison to 
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ACPA-negative patients.7 ACPAs are perpetuated by environmental factors such as smoking.7 
RA proves difficult to treat since individual patients experience varying levels of inflammation, 
locations of RA and severity of pain thus the analysis of biomarkers such as autoantibodies, like 
ACPA and RF, help health care providers create treatment plans and predict the success of said 
treatments for each individual case of RA.2,13 Due to the very nature of biomarkers, however, 
they alone cannot be taken as proof for susceptibility to the autoimmune disease RA as they 
indicate other autoimmune diseases or infections as well.7 Nonetheless, research has indicated 
that in increase in autoantibodies ACPA and RF are highly indicative of future RA 
development.2 
A review published by C. Croia et. al. disclosed a list of the most likely environmental 
factors that contribute to RA, as described in any 2019 articles published on RA. Amongst the 
list were factors such as smoking, dietary habits, obesity, infections and others.1 Obesity was 
shown to correlate with increased risks of RA for women.1 This correlation is thought to be 
caused by adipokines such as leptin which are cytokines released from adipose tissue.1 Leptin 
may, in fact, be a player in inflammatory response and bone erosion.8 While obesity has been 
shown to correlate with an increased risk of RA, cigarette smoking nearly guarantees 
development of RA.1 Studies have indicated that cigarette smoking  is the most pertinent external 
environmental factor to prompt RA.1 In fact, mouse models exposed to cigarette smoke (CS) 
condensate expressed arthritis one day after exposure.1 However, the mechanisms effected by CS 
are uncertain. Nonetheless, there appears to be a strong positive correlation between smoking 
and the risk for rheumatoid arthritis. The list of factors that contribute to the potential for one to 
develop rheumatoid arthritis is extensive however, so there is still great debate amongst the 
scientific community as to the causes and foolproof indicators for RA.15 
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Gene Expression 
 Rheumatoid arthritis is largely considered a genome-based and environmentally 
influenced autoimmune disease.3 Current studies discovered the HLA-D1 gene clearly partakes 
in RA morbidity, however its influence on the disease is yet to be fully understood.1 Genome-
wide association studies (GWAS) have indicated there are over 100 loci (genes) that are in 
association with an increased risk of RA.1 
 HLA, human leukocyte antigens, are MHC class II surface receptors which are encoded 
by the HLA complex present on the sixth chromosome in humans.1,16 Three classes of HLA 
exist, and they are all glycoproteins bound to the cell surface.1 Class I HLA and Class III assist in 
the process of peptide presentation inside the cell and play a role in the complement system 
activation, respectively.1 HLA class II is the lynchpin for displaying peptides on the outer surface 
of APCs.1 Without HLA class II it would be an anomaly for T helper CD4+ T cells to be 
activated, thus preventing a well-rounded immune response.1 
ACPA, an autoantibody and indicator for the onset of RA, is tested in potential RA 
patients and determined as either present or absent.1 Prior research once indicated there was a 
difference in genetic susceptibility for ACPA-positive patients as compared to ACPA-negative, 
but this has since been disproven showing no difference in the heritability of RA when studied in 
twins.1 The severity of disease manifestation, however is indicated by a APCA-positive test.1 
Citrullination, the “C” in ACPA, is a posttranslational modification that occurs when a charged 
arginine is replaced by a neutral citrulline on self-proteins (proteins which ordinarily abide in the 
body).1 The variable region of these citrullinated antibodies have unique N-linked glycans 
(especially on ACPA-IgG) which is likely the physical difference between ACPAs and 
nonpathogenic antibodies.1 Specifically generated by citrullinated B cells, ACPAs react with 
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citrullinated autoantigens within the blood and articular cartilage.1 For instance, citrullinated 
fibrinogen is normally present within the blood plasma, however during inflammation events the 
levels of citrullinated fibrinogen increases nearly threefold.17 This autoantigen glycoprotein 
complexes with ACPA to stimulate Fc𝛾 receptors on macrophages. Fc𝛾 receptors then signal for 
the release of TNF-𝛼, a proinflammatory cytokine, thus eliciting an immune response.1 
Therefore, ACPA leads to an intensified and autoreactive response, all beginning with the 




Figure 5: A detailed analysis of how HLA-DRB1 gene expression interacts with the 




HLA is a relevant gene to RA pathogenicity because of its relationship with ACPAs.1 
HLA expression is similar in both young-onset and normal RA, which indicates its role is of 
unique importance regardless of age.1 HLA-DRB1 is associated with positive ACPA RA, in 
particular.1 There has long been a hypothesis concerning three amino acid sequences 
[70QRRAA74, 70RRRAA74 or 70QKRAA74 (where R is Arginine, A is Alanine and K is 
Lysine)] which are commonly referred to as the “shared epitope” (SE).1 The presence of these 
SE in the HLA-DRB1 gene is thought to allow for self-antigens to be presented to T 
lymphocytes.1 Approximately 75% of patients with RA have the HLA-DRB1 SE allele.18 Indeed, 
RA development is three to five times higher in patients with the SE allele than in those who do 
not.1  There are several loci within the HLA class II region that have been shown to play a role in 
RA: HLA-DP, HLA-DQ, and HLA-DR.1 HLA-DRB1 shared epitope is also strongly associated 
with ACPA-positive RA and the overall presence of autoantibodies.1 HLA-DRB1 SE also 
corresponds with increased mortality, though interestingly SE is most common in men, not 
women which is the population group which is normally most susceptible to RA.1 Perhaps one of 
the most interesting findings concerning HLA-DRB1 SE is its relationship with cigarette 
smoking (CS). This environmental factor, coupled with HLA-DRB1 SE, positively correlates 
with an increase in autoantibody production in RA.1 Specifically, there are six exons on the 
HLA-DRB1 gene.1 (This is the location on a gene where the information for coding a protein or 
peptide is stored.1) Exon 2 is where the antigen recognition site for coding antigen recognition is 
housed, therefore Exon 2 in the HLA-DRB1 gene is crucial to the potential changes in immune 
recognition that leads to RA.1  
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 HLA-DRB1 is not the only gene thought to influence or be influenced by RA 
pathogenesis.1 The list is quite exhaustive (over 100 genes have been identified), but there is a 
handful of genes which are more noteworthy than the others.18 CD97, FYB, CXCL1, IKBKE, 
CCR1 are genes which play a direct role in immune response.18 CD97, CXCL1, C3 AR1, CCR1, 
and LYZ induce inflammatory responses, and C3 AR1, CCR1, PLN, CCL19, PPT1 are involved 
in homeostasis.18 Some of these genes, such as CXCL6 and CXCL1, are part of the same C-X-C 
motif rather than two entirely distinct genes.18 Each RA-related gene plays an intricate role in 
RA as expressed in the supporting literature extensively.1,18,19 CXCL1, for instance, is known to 
powerfully attract neutrophils in the synovial tissue and fluid of RA.1 This heavy attraction is 
triggered by TNF-𝛼 or IL-1𝛽 both being key players in RA.18 Studies such as the microarray 
depicted in Supplemental Data 1 have been shown as an effective gene analysis tool.20 Indeed, 
much more research is needed in the area of gene expression for RA considering the vast 




Current Treatments  
Treatment Course of Action 
Symptom-based treatment options are available for patients with RA. Since each case of 
RA can vary in pain intensity, bone degradation and an individual’s response to pharmaceuticals, 
there are a slew of treatment options. Nonsteroidal anti-inflammatory drugs (NSAIDS), 
corticosteroid medications, and various forms of disease-modifying antirheumatic drug 
(DMARDs) agents are the most common forms of drugs used to combat the symptoms.22 Since 
most patients experience joint damage as early as two years into their initial diagnosis, early 
treatment in the beginning months of diagnosis is of the utmost importance.5 Physicians 
prescribe drugs depending on the severity of each case in order to control inflammation, and 
potentially achieve remission for their patients if the treatment is prompt and effective.22  
In addition to d25rug intervention is the importance for patients to be educated about the 
importance of exercise and physical therapy.22 Weight bearing exercises have been shown to 
particularly aid in the retardation of RA symptom onset.22 According to studies of biomarkers, 
RA is perpetuated by factors such as obesity and smoking, so patients with RA who take 
preventative measures against these conditions and habits will only benefit in the long-run for 
their disease remission outcome.7,22 
Unfortunately, due to the autoimmune nature of RA and the severity of its progression, as 
well as the intensity of immunosuppressing drugs, many patients are backed into a metaphorical 
corner. They are crushed by the trifecta of severe pharmaceutical side effects, grating pain or 
living in a constant state of immunosuppression. It is for these reasons that one of the greatest 
current struggles in treating RA is the ineffectiveness of drugs for long-term remission.22 Given 
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RA has both genetic and environmental factors which contribute to its development, it is 
imperative to assist patients in taking preventative measures against this disease. 
The European League Against Rheumatism (EULAR) has compiled a three phase, 
multifaceted set of 10 recommendations for how to treat RA as well as a pointed, target-to-target 
approach for optimal patient outcome.22 Supplemental Data 3 depicts said recommendations.22 
The treatment process is split apart in three phases, each dependent on how a patient responds to 
the selected pharmaceuticals and if a target outcome has been achieved.22 Methotrexate, an 
immunosuppressive antimetabolite DMARD drug, is often suggested as the initial treatment for 
RA, however if a patient reacts poorly to methotrexate or other conventional synthetic DMARDs 
(csDMARDs), alternative DMARDs can be prescribed.22 Either of these treatments can be paired 
with short term, low dose glucocorticoids.22 If these combinations fail to aid in decreasing 
inflammation and pain after six months, a patient enters phase II.22 Characterized by the addition 
of biologics, otherwise known as biologic DMARDs, treatments with a targeted DMARD “TNF-
inhibitor” or an “IL-6 inhibitor” in this phase heightens the intensity of drugs used to fight 
progressing RA symptoms.22 This pharmacological approach was discovered largely by 
analyzing the effects of HLA-DRB1 SE in RA patients.1,16 If a patient moves into phase III 
recommendations, alternative biologics are prescribed.22 A Janus kinase inhibitor (JAK-
inhibitor) is a recent discovery and last resort for treatment options.22 Importantly, if an 
individual experiences positive results from any of the treatment in the various phases, the drug 
regimen is not discontinued, rather it is repeated indefinitely in order to maintain anti-
inflammatory effects, decrease pain and potentially increase quality of life.22 The hurdle for 
long-term remission in so many RA cases however is the ability of the immune system to create 
antibodies against the biologics introduced to it. 
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Glucocorticoids 
During the early disease state of RA, glucocorticoids (GC) may be utilized in order to 
control inflammation, swelling and relieve pain quickly.22 GCs are a subgroup of steroids, 
therefore, their use is most effective for short term, 3-4 month, periods and are not recommended 
to be used longer than that time frame due to their harsh side effects and possible 
comorbidities.22,23 Therefore, GCs can be replaced by or paired with DMARDs for long-term 
inflammation dampening.22 GCs are effective against inflammation due to their mechanisms of 
action by inhibiting B and T cells.23 GCs suppress proinflammatory molecules in a process 
known as transrepression.22 The opposing but simultaneous action of GCs is transactivating anti-
inflammatory molecules.22,23 Transactivation is thought to cause adverse effects within the body 
during chronic use of GCs.22 A few of the adverse side effects include weight gain, fat 
redistribution such as a buffalo hump as shown in Figure 7 (buffalo hump source), osteoporosis, 
fractures, cardiovascular effects such as atrial fibrillation, flutter, and heart failure, increased risk 
of infection, and lastly, hyperglycemia.21,23,24 Patients are more likely to experience serious 
Figure 6: Buffalo hump, or the accumulation of adipose tissue on the 
neck and trunk of a male rheumatoid arthritis patient. (View is both 
lateral and posterior).21 
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effects such as these if GC use is prolonged, so they are rarely prescribed on a long-term 
treatment regimen.22,23 Disease-modifying antirheumatic drugs can therefore be prescribed in 
conjunction with or in place of glucocorticoids.22,25   
Methotrexate 
 Methotrexate (MTX) and other conventional DMARDs dampen the inflammatory 
response via several modes of action including downregulating the production of TNF.22 
Methotrexate is one of the most commonly prescribed conventional synthetic DMARD 
(csDMARD) though its high dose related side-effects are severe and can be life threatening.22,25 
The milder side effects of low-dose MTX are WBC and platelet deficiency, headaches, 
gastrointestinal complications, but many of these can be subdued by folate supplementation.22 
Folate supplementation is necessary because MTX treatment causes the body to dispel it at 
higher rates than in normal function.26 This affects a person as a whole because folate helps 
prevent anemia, aids in tissue growth and cell action and is all-around essential to normal bodily 
functioning.26 MTX can be replaced with other DMARDs such as leflunomide, 
hydroxychloroquine or sulfasalazine if a patient reacts poorly to MTX; these drugs express 
similar success to MTX.22 
The process of determining which drug is most effective for an individual can be long 
and grueling. The effects of MTX are often not experienced until 12 weeks into consistent oral 
ingestion of the drug either once a day or weekly depending on recommendations.22 After 24 
weeks of drug treatment, then a decision can be made as to whether or not MTX is assisting in 
remission of RA.22 This drawn-out effect thus can leave many patients frustrated with their 
treatment and lead them to discontinue the drug unsafely.22  
Tumor Necrosis Factor-Alpha Inhibitors 
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 Tumor Necrosis Factor-Alpha Inhibitor (TNFi) is unique compared to GCs because they 
are antibodies which target tumor necrosis factor (TNF) within the immune system.22,27 TNFi is a 
biologic meaning it is composed of large antibodies which were derived from living cells in a 
laboratory setting.28 Biologics can be large or small molecules and are not always antibodies, 
regardless, they always target either a specific genotype or protein receptor.28 In the case of 
TNFi, it targets the latter.28 Recall, TNF signals for proinflammatory cytokine production, such 
as IL-6, and inhibits Treg cells.
19 There are currently five TNFi available for treatment and while 
each can be utilized to combat various diseases all can be applied to RA treatment, the most 
common of which is Infliximab.22,27,29 TNFi acts to hinder TNF by binding to its correlating 
receptors present on nearly all types of cells other than erythrocytes.27 The two receptors to 
which TNF normally binds are so1TNF and tmTNF which signal for inflammatory response and 
increased sensitivity to infection, respectively.27,29 The issue with TNFi is its non-selectively.29 
TNFi blocks both the receptors TNF normally binds to which is beneficial for anti-inflammatory 
effects but of detriment for the ability of the immune system to fight infection.29 
IL-6 Inhibitors 
An IL-6 inhibitor binds more specifically than TNFi’s.22 This inhibitor prevents the 
actions of IL-6, a cytokine abundant in the synovium of RA patients and known for its 
proinflammatory activation.22,30 IL-6 may contributes to B-cell differentiation in turn producing 
autoantibodies such as RF and ACPA.30 IL-6 also induces differentiation of T-cells into IL-17 
secreting Th17 T helper cells thus preventing Treg divergence.
31 To add insult to injury, quite 
literally, IL-6 may encourage synovial fibroblast changes and osteoclast activation leading to 
further degradation and annihilation of cartilage and bone matter.30 
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IL-6 inhibitors are most commonly monoclonal (synthetically produced antibodies) that 
bind to both membrane-bound and soluble IL-6 receptors, hence blocking the option for the cell 
to signal for others hence preventing an increase in inflammatory response.17 The common 
prescription IL-6 inhibitor is Tocilizumab.30(p6) IL-6 continue to be normally produced by the 
innate immune system cells such as macrophages, and neutrophils, as well as adaptive immune 
B-cells, but they are rendered inactive when an IL-6 inhibitor binds to its receptors.32 Unlike 
other inflammatory diseases whose inflammation is characterized by TNF, IL-6 is thought to 
indicate inflammatory response and the pathogenesis of RA.32 In terms of treatment with IL-6 
inhibitors, a patient may be able to receive intravenous drip infusion once every four weeks with 
dosage depending on clinical response. The benefit of this treatment is that its impact, whether 
null or positive, is observable more quickly than TNFi or MTX treatment options.30,32  
JAK-Inhibitors 
The final resort for many RA courses of action is a Janus-Kinase Inhibitor. Drugs such as 
tofacitinib are JAK-inhibitors, targeted, synthetic DMARDS (tsDMARDS) with a mechanism of 
action that blocks tyrosine kinase.22 JAK are tyrosine kinases present in the cytoplasm.22 There 
are 90 forms of Jaks which fall into four categories: Tyk2, Jak1, Jak2 and Jak3.33The JAKs 
pertinent to RA play an intricate part in signal transduction to the nucleus from interleukins and 
act as downstream mediators for pro-inflammatory cytokines such as IL-6.22,33 This downstream 
effect is possible because when JAK and cytokines bind, phosphorylation of signal transducer 
and activator of transcription (STAT) molecules occurs (hence the “kinase” characteristic of 
JAK).22 The phosphorylated STATs then dimerize and can enter the nucleus leading to increased 
signaling for inflammatory response- a system that is expressed in Figure 7 (Janus Kinase 
inhibitors source).22 The Jak/STAT pathway is often utilized by cytokines to exert their effects 
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and therefore JAK has become a promising target for recent therapeutics.33 Concerning RA, the 
two available drugs target JAK1/JAK2 or Jak1/JAK3, specifically.33 Tofacitinib blocks Jak1 and 
Jak2 thus preventing Th17 cells from generating. This action prevents the production of a 






























Figure 7: JAK-Inhibition Mechanism. Cytokines bind to receptors, thus eliciting an intracellular 
phosphorylation of the tyrosine kinase receptor. STATs are signaled for, phosphorylated by JAKs and 
as a result become dimers. STATs play a large role in regulating gene transcription, therefore, JAK 
inhibitors target the initial phosphorylation of STATs via JAK. Listed are a number of known JAK-
inhibiting drugs.33 
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Cigarette Smoke and E-Vapor 
Cigarette Smoke 
Cigarette smoke (CS) has long been considered the leading environmental factor to 
contribute to RA pathogenesis.6 Studies indicate that smoking one pack of cigarettes a year, 
which is equivalent to 20 cigarettes, increases the likelihood of contracting RA by 26 percent; 
this susceptibility only increasing as the number of cigarettes smoked throughout a person’s 
lifetime increases.6  
Two of the most critical factors for CS exposure as it pertains to RA development are 
intensity and duration, though duration is most impactful.6 For instance, an individual who 
smokes throughout the course of his/her life is far more likely to be diagnosed with RA than an 
individual who chain smoked (consecutively smoked one cigarette after another) cigarettes at a 
social gathering once during their youth. However, both duration and intensity do play a role in 
RA development.6 Interestingly, autoantibody production in smokers is much higher than 
nonsmoking individuals, additionally, even if smokers test negative for RF and ACPA, their risk 
for RA is still heightened compared to nonsmokers.6 CS breaks the tolerance the immune system 
has for autoantigens naturally present in the body, according to Ishikawa et al., thus triggering 
RA development.6 While both RF and ACPA are the most common autoantibodies present in 
people with RA, RF is present at higher rates within smokers than nonsmokers, while ACPA-
positivity increased dramatically in the smoking population.6  
The effects of CS are of both short term and long-term detriment. There reaches a certain 
point that the damage from chronic CS in ACPA-positive patients can no longer be undone thus 
decreasing RA treatment outcomes.6 On the other hand, if a person has ceased smoking for more 
than twenty years, the level of ACPA-negativity increases along with improved outcomes for RA 
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treatment and potential remission. The potential improvement of RA outcome for smokers in 
longtime remission is an implausible outlook for chronic smokers.6 This stark contrast is once 
again thought to be due to the importance of duration verses intensity.6 Crucially, CS is not only 
detrimental when experienced first-hand, but also in a second-hand, “passive,” capacity. 
Children who experience passive CS have indicated a greater risk for RA in adulthood though 
this is a tentative correlation and must be further explored.6 This observation further solidifies 
the hypothesis that duration and intensity play key roles in how CS influences RA susceptibility.6  
Cigarette Smoke Immune Impact 
 Without question, CS impacts both cellular and humoral immunity, thus inducing a 
systemic inflammatory response both via the innate and adaptive immune systems.6 The difficult 
factor in CS is the way it impacts the human body is diverse and far-reaching. Direct inhalation 
of CS, as well as passive CS, is a known cause or strong factor in many diseases, including but 
certainly not limited to, heart disease, stroke, diabetes, lung disease, lung cancer, COPD, sudden 
infant death syndrome, and asthma.22 Therefore, to determine the exact mechanisms by which 
CS passive or active affects RA is no small feat (Figure 8).23  
One repercussion of CS is observed in Th cells acting with skewed effect in RA.6 Th17 in 
particular is a cell of interest in RA development due to its active role in signaling for neutrophils 
and inflammatory cytokines from other T cells during the early stages of RA.6 As divulged in the 
Current Treatments section, many pro-inflammatory cytokines proliferate exponentially during 
RA pathogenesis.6 Th17, TNF-𝛼, IL-6, IL-1𝛼/𝛽, and IFN-𝛾 all proliferate at staggering rates, 
and have therefore been targets for treating RA via DMARDs such as methotrexate or JAK 
inhibitors.6,24 CS becomes a catch-twenty-two when treatment options are analyzed however 
since at first glance it would seem as though smokers have many options for pharmaceutical 
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treatment due to the increased presence of target molecules for said therapies. CS adds yet 
another layer of complexity to treating RA however by negatively influencing the effectiveness 
of these drugs.6 Drugs such as infliximab, a biologic DMARD, therefore has little effect on the 
disease.6,24 
Figure 8: Pathogenesis of Rheumatoid Arthritis. Genetics and environmental 
factor interactions for rheumatoid arthritis. Results of this relationship leads to 
loss of tolerance of self-proteins such as B and T cells. Transitioning to arthritis 
this translates to structural damage of the joints, and other bodily systems.23 
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Vaping and E-Vapor Components 
 Smoking e-cigarettes, commonly referred to by younger generations as “vaping,” 
continues to grow in popularity within the United States, and globally.25 Within the last year, a 
national study indicated that more than 10% of youths ages 15-17, and 11% of 18-21 year-old 
young adults have smoked Juuls.7 This does not include any of the other forms of e-cigarettes 
(electronic cigarettes) on the market, of which the CDC indicates there are many.7 Interestingly, 
vaping, unlike cigarette smoking, has a large appeal to broad groups of people, therefore, there is 
a more nonchalant acceptance of it amongst school-age children, as well as adults, regardless of 
their distinctly differing opinions concerning the harms of CS.26 In fact, many young people 
realize the harmful effects vaping has been shown to lead to, but the social aspects of vaping 
outweighs those facts.26 
Ranking from least to most popular for customer consumption, disposable e-cigarettes, 
rechargeable e-cigarettes such as Juuls, and tanks or mods are a few of the broad categories 
available to “vape” with (Figure 9).25 Juuls are particularly desirable in the eyes of middle and 
high schoolers because of their compact size and USB drive appearance which allows for quick 
and unassuming storage, however Juuls are a highly effective vessel for nicotine inhalation as 
well.25 The benefit to Juuls are that they seem to be less harmful than CS or other e-cigarettes in 
term so the carcinogens present within them.7  
Figure 9: Various forms of vape devices as described by the Center for Disease Control 25 
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Within the vaping industry, each smoking mechanism product appeals to a different 
purpose of the user. For instance, disposable electronic cigarettes are the most affordable option 
and provide users affordable and speedy mechanism for nicotine.27 Traditional e-cigarettes are 
considered a weaker form of vaping.27 Box mods are incredibly popular due to their powerful, 
sub-ohm systems. Sub-ohm systems are often set to lower temperatures to allow the user to 
deeply inhale the e-vapor aerosol into his/her lungs. These models are more sophisticated than 
other vaping options, with complex systems to control various wattage settings, temperature 
control options, and are able to hold large amounts of e-liquid.27 These are often the models 
utilized by experienced vapers because of their high capacity for release of aerosol, which allows 
for various tricks and smoke maneuvers to be performed.27 
All of the available e-cigarettes, hereby referred to as vaping devices, share common 
generalities in their functions. They produce an e-vapor aerosol (of which contains various 
chemicals, flavors or addictive substances) by heating an e-liquid, “juice,” via battery power 
producing heat via coils.25  
The general consensus on e-vapor aerosol inhalation, referred to as vaping is that it is 
considered less detrimental than CS.28 This viewpoint stands as popular opinion since these 
modes of nicotine inhalation contain fewer carcinogens than cigarettes for those hoping to quit 
smoking cigarettes.25 There are also non-nicotine forms of juice available to be vaped depending 
on what type of model is used, and studies have indicated that these do not lead to compromised 
bone integrity.28 It seems as though even without the component of nicotine being introduced to 
an organism, RA is perpetuated due to the alternative chemicals and toxins within cigarette 
smoke.9 On the contrary, research also indicates vaping is likely as detrimental, if not more, than 
CS, depending on the model and juice utilized.7,25  
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E-cigarette aerosols contain volatile organic compounds, nicotine, ultrafine particles 
which are detrimental to the lungs, heavy metals such as nickel, tin and lead, cancer-causing 
chemicals, and flavoring such as diacetyl (which is linked to serious lung disease).25 There are 
generally fewer carcinogens within e-cigarettes than traditional cigarettes (TC), however, they 
are replaced by propylene glycol (PG), vegetable glycerin (VG) and flavoring which masks the 
taste of toxins (unlike that of traditional cigarettes TC).29 Table 1 indicates the five most 
common ratios for these two liquids alongside the most commonly purchased vape juice 
flavors.27,29 Each concentration of vape elicits a different vape experience, thus juices are chosen 
based on individual preferences. Additionally, vape juices commonly contain anywhere from 0 
mg, 3.0 mg, 6.0 mg, 12.0 mg, 18.0 mg, or 36 mg of nicotine per 1 mL which allows users to pick 
and choose their desired nicotine level for many of the juice options currently on the market.28 
E-Vapor and Adolescents 
Table 1: Vape Juice Breakdown and Various Juice Flavors. VG is a thicker liquid thus eliciting a thicker 
more robust vapor with little flavoring. PG, however, is a thinner liquid ideal for flavor carrying and 
inhalation felt on the throat. Therefore, vape juice is often purchased and utilized depending on an 
individual's user's preferences 
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 Vaping is a fairly new form of smoking that is everchanging with its growing appeal due 
to its hypothetical superiority to CS.30 Though e-cigarettes are hypothesized to be a less harmful 
method for TC smokers to quit smoking or improve chronic asthma as well as COPD outcomes, 
there is a downside to e-vapor.30 Vaping has gained widespread popularity amongst adolescents 
and young adults. According to the American Journal of Preventative Medicine, youths view 
tobacco harm on a spectrum ranging based on the vesicle by which it is exposed to the body.31 
In 2017, electric cigarettes were the most regularly purchased from of tobacco by middle 
school and high school aged adolescents.30 An additional 1.3 million teens began vaping in 2018, 
alone. One can only speculate as to how many youths are partaking in vaping in the year 2020- 
approximately 16 million youths is once recent estimate.30 Unfortunately, vaping companies 
quickly realized the appeal vaping had amongst youths, and began marketing on social media 
platforms, receiving celebrity endorsements, and promoting vaping with cartoon images, sexual 
appeal and sleek marketing tactics.30 The perception of vaping being safe was therefore 
compounded by the advertising of these companies.30,32 These companies have since been 
rebuked and directed to refrain from such forms of advertising, however, the attraction to vaping 
lives on amongst middle and high schoolers.30 
E-vapor Effects on the Body 
Vaping has been shown to greatly affect oxidative stress (OS) due to an increased 
generation of reactive oxygen species.30 Reactive oxygen species play a detrimental role in 
health, often contributing to pathogenesis of diseases that occur in the respiratory system, 
metabolic actions and neurodegenerative diseases.30 Oxygen reactive species are also key players 
in the effects of addiction and dependence.30 These species play a role in smoking addiction, 
morphine addiction, alcohol and cocaine addiction and methamphetamine addiction.30 
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Specifically, vaping could be an influential contributor to depression and suicide, sleep 
deprivation and attention deficits, as well as aggressive, impulsive behaviors.30 Ultimately, these 
outcomes are not on the list of characteristics commonly associated with the success for the 
future generation, therefore, it is imperative to study the true effects of vaping in order to better 
understand the long term effects it may have on adolescents.30 Though there are many 
contributors to the steady increase in depression and suicide within the United States, TC 
smoking is strongly associated with major depressive disorder among teens.30  Similarly, vaping 
use is associated with an increase in suicide ideation- as seen by an increase in reactive oxygen 
systems and their link to suicide and suicide attempts.30 Beyond mental health, adolescents who 
vape have been shown to express lower academic performances than their non-vaping peers.30 
Cognitive deficits, memory impairment, attention deficits and alertness, and the disturbance of 
the development of the cerebral cortex and hippocampus are all strongly associated with TC 
smoking.30 At this point, it is critical to note that both first and second hand smoke from 
cigarettes has been shown to effect teenage sleep patterns, sleep deprivation, and therefore poor 
academic performance.30 There needs to be extensive further studies concerning the effects on 
adolescent health specifically pertaining to e-vapor, however. One study indicated the effects of 
vaping was not, in fact, from the vapor itself, but rather the effects of nicotine in the aerosol.30 
Yet another study contradicts that data and indicates that oxygen reactive systems increased after 
e-vapor alone.30 Due to the vast options available for vaping juice flavors, nicotine or non-
nicotine content, as well as the density of the vapor and aerosols, countless studies with various 
combinations could be performed.30  Lastly, long term studies must be performed to analyze the 
long term effects of vaping on teens and young adults; only minimal research has been 
performed in this area, pertaining to less than four years after vape exposure.30 
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The general population often considers smoking TC or e-vapor with their potential effects 
on respiratory health.33 This association is well founded for TC, while the little research 
conducted on e-vapor effects is indicative of strong negative effects.33 One study discovered that 
the summer of 2019 held a tremendous upward trend of vaping-induced lung injuries (EVALI).33 
In particular, vaping THC (tetrahydrocannabinol) correlates strongly with lung injuries; these 
correlations do not have bias impact based on age bracket. Whether young or mature adult, the 
effects of vaping THC specifically have proven to be detrimental.33 Young males who vape have 
been shown to experience fever, chills, headaches, chest pain, coughing and shortness of breath. 
Correspondingly, gastrointestinal issues such as pain, nausea and vomiting are common.33 The 
effects of e-vapor are characterizable even after two days of exposure; acute lung injury, diffuse 
alveolar damage and organizing pneumonia are a few of the quickly onset conditions perpetuated 
by vaping.10 In conjunction with these disease onsets, chest CAT scans indicated ground-glass 
opacities (Figure 10).10   
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In comparison to TC, there is little data on the true physiological effects of e-vapor via 
the newest forms of e-cigarettes known as vape pens, mods or tanks. This lack of data leaves 
much to be desired in terms of the repercussions of vaping- particularly its effects on the next 
generation. With the increasing appeal to vaping due to unique smokable flavors, and diverse 
tricks and purposes behind each type of vaping, the adolescent population continues to consume 
this product with minimal evidence as to how it is impacting their health days, months and 
decades from now.  
  
Figure 10: Ground-glass Opacification. CAT scan reveals normal lung (right) versus 
ground-glass opacification (right). Ground-glass opacification within the lungs is 
common in patients with histories of chronic smoke inhalation, such as with vaping.10 
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Laboratory Research Proposal 
Rheumatoid Arthritis is the leading form of arthritis, as well as one of the most prevalent 
autoimmune diseases. Likely initiated by gene expression abnormality, as well as environmental 
factors such as cigarette smoking, and potentially e-vapor, RA pathogenesis is complex and 
treatment plans complicated. Though this disease is most common amongst women who are 
forty years of age or older, RA susceptibility has been shown to increase with CS exposure. 
Since vaping was first introduced in 2007 it has become one of the most popularly consumed 
form of nicotine products on the market. In particular, vaping has a large appeal amongst 
adolescents. Cigarette smoking has been shown to increase the likelihood of RA induction 
exponentially, therefore there may be a similar connection between RA susceptibility and 
inhalation of e-vapor. Little research has focused on the effects e-vapor may have on the body; 
therefore, the need arises for this novel study. Primarily, studies as to whether or not vaping 
worsens the progression of RA must be explored; furthermore, the HLA-DRB1 gene expression 
pathway, as well as autoantibody (RF and ACPA) proliferation should be investigated since 
these factors are key players in CS exposure and RA pathogenesis. 
Specific Aims  
The objective of this research proposal is to determine the potential effects of vaping on 
adult susceptibility and the pathogenesis of rheumatoid arthritis. Moreover, the effects of chronic 
e-vape inhalation in adolescents and young adult will be analyzed to determine in order to 
determine a potential increase in rheumatoid arthritis onset later in life. These experiments will 




Preparing Arthritic Mouse Models 
All of the mice will be treated according to the appropriate handling of vertebrate animals 
as laid out by national guidelines and study protocol and kept within individually ventilated 
cages in 12-hour light/dark cycles. Likewise, food and water will be available to the animals ad 
libitum.34 They will also be acclimated to the nose-only exposure chamber prior to experimental 
vapor exposure. The background genome for both the experimental, sham and control groups of 
this experiment are C57Bl/6 mice. Historically, active immunization causing collagen induced 
arthritis most closely resembles that of RA within mouse models, so this will be induced in the 
mice. At 8-10 weeks of age the mice will be injected with a 100 ug tail base injection of CII 
dispersed in complete Freunds adjuvant (CFA) at day zero.35 This method was chosen because 
CFA allows for a water-in-oil emulsion of antigens that act upon the synovium of the joints.36 At 
day 21, these mice will receive a boost of another 100 ug CII of incomplete (IFA) to ensure 
proper induction of arthritis via plasma cell activation.35 
CRISPR-CAS9 
 Discovered in 1987 and further understood in 2007, CRISPR-Cas9 is a new technology 
based on a system naturally found within bacteria to ward off viral infections.37 Two short RNA 
chains form a complex with the Cas9 nuclease (DNA cutting) protein.37 This complex allows 
Cas9 to identify the portion of the viral DNA that is detrimental to the bacterium via a guide 
RNA.37 This specific portion of DNA is then cut from the genome and replaced with a target 
RNA strand. If the match is completed, then the DNA is cut, forcing the cell to begin the repair 
process.37 Due to errors that occur in the repair process, however, the gene which CRISPR 
interfered with becomes inactivated, allowing the observation of the function of a now disabled 
gene.37 This technology is applicable in any genome, even humans, and certainly mice, therefore, 
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it will be utilized within Specific Aim II in order to study the downstream effects of silencing 
HLA-DRB1.37   
Specific Aim I: Vaping worsens Rheumatoid Arthritis.  
This aim primarily seeks to lay the foundation for all following experimentations. 
Cigarette smoking has long been considered the strongest environmental factor to contribute to 
rheumatoid arthritis (RA) induction. The pathway of said influence has yet to be solidified, 
however, with the HLA-DB1 pathway presented as the most likely expression pathway for the 
immune changes that ultimately lead to onset of RA. Therefore, based on the most readily 
available research, this proposal hypothesized that e-vapor and its components may follow a 
similar pathway for RA induction as CS. Regardless of pathway however, it is proposed that 
vaping will induce more severe RA symptomology than non-vape exposed mice. There is a great 
need for this particular study due to the exponential rise of popularity for vaping amongst 
adolescents and young adults. The trend of vaping has only continued to grow since it was first 
introduced 2007, with little to no hard data and research on the repercussions of e-vapor. 
30 C57Bl/6 CIA mice will be equally split between two groups of experimental mice. 
Additionally, the sham and control groups will consist of 10 mice each. The experimental and 
sham groups will be placed on an inhalation regimen for CS, e-vapor and filtered air, 
respectively via a nose-only aerosol exposure system Figure 11.28,34,38 The experimental mice 
will be exposed to nose-only inhalation for up to 4hours/day, 5 days a week (a total of 14 days) 
in order to mimic chronic CS/e-vapor/filtered air inhalation.28,34,39 Conversely, the animals will 
be allotted time to acclimate to the nose-only inhalation and therefore exposure time will 
increase from 1 to 4 hours by one hour increments for the first four days of treatment.40 The mice 
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will be exposed to an average of one puff of smoke/vapor per 30 seconds, with a 3 second puff 
duration.40 The protocol for exposure is carried throughout Aims I-III. 
Mice exposed to CS will inhale 3R4F Kentucky reference cigarettes, as these are 
commonly utilized within CS studies.35 E-vapor mice will be exposed to a 50PG/50VG/4% 
nicotine vapor based on weight consistent with a previous study concerning vapor effects.35 The 
mode of vape utilized will be via a SMOK RPM 80 POD MOD which is known to be the middle 
ground mod style for beginner and expert vaping individuals since the goal of this proposal is to, 
as accurately as possible, analyze the impact of vaping as it is performed by adolescent 
consumers in the future aims. The specific dimensions and features of this mod can be found in 
Supplemental Data 3.41  
Figure 11: Nose-only Aerosol Exposure System. Utilized to standardize the inhalation 
and exposure time of mice to the various experimental smokes (CS, e-vapor, filtered 
air). Each mouse is housed within an individual tube with its nose exposed only to the 
central chamber which is pressure controlled to allow even distribution and 
concentration of the aerosols from attached generators.28 
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Several studies have been conducted concerning the effects of simplistic e-cigarettes, but 
little to no research has been performed in the area of the most common forms of vaping to date.  
The central hypothesis for this experiment is that RA expression in both the CS and 
vaping group is affected, while it is not affected in the sham and control models. This will be 
determined by using a clinical arthritis score of a possible 28 points, paw volume, ankle 
thickness measured via caliper and ELISA to determine ACPA and RF autoantibody levels 
within blood serum and synovium.35,39,42 These results would indicate not only a solidification of 
numerous previous studies pertaining to the effects of CS, but also the potential correlation 
between vaping exposure and a perpetuation of RA in the CIA mouse models.  
Specific Aim II: To determine whether RA is worsened when exposed to vaping in HLA-
DRB1 knockout (KO) models. The C57B1/6 CIA mouse model, and a CRISPR-Cas9 modified 
mouse model will be used, respectively. Therefore, the groupings for this experiment will be as 
follows: 15 C57Bl/6 CIA mice with nose-only exposure to vape, 15 C57B1/6 CIA, HLA-DRB1 
KO mice exposed to e-vapor, 15 sham mice inhaling filtered air via nose-only exposure, and 10 
control C57Bl/6 mice. 
The levels of autoantibody proliferation will be measured before and after treatment via 
ELISA, RA symptomology analysis will follow suite to Aim I protocol, and a micro assay will 
be performed to yield data on gene expression. In order to study the effects of HLA-DRB1 in 
experimental C57Bl/6 mice with CIA, micro arrays will be utilized following the protocol 
previously stated.43 
The perspective outcomes for this aim are to see a significant increase in autoantibody 
presence within the synovium and blood serum of mice exposed to vapor. This promising result 
would advance the current hypotheses that autoantibodies are a necessary prerequisite to RA 
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pathogenesis. Addedly, one would anticipate the HLA-DRB1 manipulated upregulation to 
worsen RA, regardless of a vapor-less exposure. Though this particular focus of the study may 
prove unsuccessful in the desired results of HLA-DRB1 pathway upregulation triggering RA 
pathogenesis, the results would be of benefit since this would create opportunities to pursue 
alternative pathways for RA activation. 
Specific Aim III: Lastly, the long-term effects of vaping on adolescent mice must be 
analyzed. There are currently no longitudinal studies concerning the effects of vapor on 
adolescent growth, development, and later the potential onset of RA. Due to the increasing 
popularity of vaping amongst middle school and high school aged students, this study is 
imperative to the health of the future generation. This long-term exposure study will be 
performed on adolescent CD57Bl/6 mice ranging from the juvenile age of 2 to 3 weeks of age 
continuing in observation until they reach 4 months of age.  
The experimental groups will be separated based on the longevity with which they are 
exposed to vapor. The first set of 15 CD57Bl/6 mice will be exposed for 14 days. After which 
they will be analyzed for autoantibody production, as well as the same criteria for RA onset as in 
specific aim I. Another experimental group of 15 CD57Bl/6 mice will be exposed to nose-only 
aerosols for two months, with the final 15 mice experiencing inhalation of vape for the full 4 
months to mimic chronic vaping tendencies. The control and sham groups remain the same as 
former experimentations have listed, except for their juvenile rather than adult state. Each of the 
experimental groups will be observed daily during the first two weeks of exposure, then then 
biweekly until they reach 6-8 months of age. 
In the final analysis of these experimental groups, the proposed results would 
demonstrate not only an elicitation of RA, but also characteristic increases in its expression and 
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symptomology due to chronic inhalation of vaping aerosols within the juvenile mice. If such 
results are uncovered, this translates to a potentially severe health outcome for teens and young 
adults who chronically smoke using e-vapor mechanisms such as the SMOK RPM 80 mod 
utilized in this study. The exponential increase in vaping since it was first released in 2007 for 
public purchase could be setting up this next generation of young people for higher rates of RA 
susceptibility when they reach their mid to late adulthoods. Not only that, but perhaps this RA 
induction due to vaping will cause excruciating and escalated pathogenicity of the disease state., 
as CS has been hypothesized to do.  
Experimental Pitfalls and Future Aims 
These experiments are anticipated to shed light on the relationship between e-vapor and 
the induction of rheumatoid arthritis as it pertains to adult and juvenile mouse models. Be that as 
it may, there are number of pitfalls within this proposal. The first major pitfall is in the form of 
the vape analyzed within the study. Most notably, standardizing the amount of vapor each animal 
is exposed to proves difficult considering how unregulated the manufacturing sector for vape 
devices is. Though the SMOK RPM 80 POD MOD may be a sound middle ground between 
simplistic and complex vaping apparatuses, it is a small portion of the potential forms of vaping 
mechanisms on the market. Due to the vast array of options available for vaping ranging from 
PG and VG concentration levels, nicotine content, an endless supply of flavorings, and the 
apparatus utilized to create vape, there are multitudes of combinations that need to be explored 
regarding the effects of vapor. Furthermore, there is currently no data depicting the longitudinal 
effects of vaping (except for a single study which examined the effects of vaping three years 
after exposure). Though there are numerous studies on the broad topic of e-cigarette smoking, 
few have focused on vaping specifically- thus leaving much to be desired for the field. 
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Specifically focusing on the experimental design, ideally, more animal models would be utilized 
in order to study this subject matter in a more robust format. Moreover, there certainly should be 
a study which focuses on the expression of HLA-DRB1 as it relates to RA. The data on this 
genetic pathway indicate strong correlations between this and that of CS, so HLA-DRB1 in-
depth investigation needed to be further analyzed both in CS exposure and vaping. In the future, 
it would prove beneficial to upregulate HLA-DRB1 expression without the presence of vape or 
CS in order to enhance results that support the role of this pathway in RA pathogenicity. Lastly, 
experiments which primarily focus on passive vaping, rather than direct inhalation of vape 
aerosols, would undoubtedly prove beneficial. Since vaping is more widely accepted as opposed 
to CS, individuals are able to vape in locations TC smokers are not permitted, thus exposing the 
general population to e-vapor. In short, the list of future experimentations concerning the effects 
of vaping appears to be ever-growing as the industry continues to grow in popularity, particularly 
amongst younger generations. 
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Conclusion and Future Aims 
 Rheumatoid arthritis is the leading form of arthritis globally, and commonly begins its 
effects on individuals in their mid to late 40’s.24 Nearly two percent of the global population is 
effected by the degrading symptoms of rheumatoid arthritis including, but not limited to, swan 
neck and boutonniere joint deformation, pain, inflammation, degreased mobility and decreased 
quality of life. 2 There is an array of current treatment options for RA that offer various tactics to 
combat the pains of RA, but with short-term and complex treatment plans a cure has yet to be 
discovered.24  
 RA is most often characterized by the presence of autoantibodies in the pre-onset stage of 
disease progression ACPA and RF being of highest significance for disease pathogenicity.5 
Though these two autoantibodies cannot be utilized as the only formal indicators of RA 
induction, they are the most common signs for RA onset and are observed in pre-clinical stages 
of the disease.2 Additional indicators such as an increase in fibrinogen synthesis, an increased 
presence of TNF-ɑ and IL-6, as well as Th17 cells produced cytokines: IL-17A, IL-17F and IL-
22 during active RA.2,44 The notable complexity of RA begins with the conundrum of what the 
initial step of RA truly is. There is large “chicken or the egg first issue” in terms of whether 
autoantibodies or self-reactive T-cells and their related cytokines are the initial perpetrators to 
RA induction.6  However, there is large scientific consensus considering the genetic and 
environmental factors which contribute to an increased susceptibility to RA.  
 Firstly, the HLA-DRB1 pathway is thought to be the primary pathway for genetic 
expression which leads to the increased proliferation of autoantibodies such as ACPA and RF.1 
Secondly, the environmental factor of cigarette smoking is the most widely accepted external 
contributor to an increased propensity towards developing RA, regardless of gender.6 CS in 
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particular is hypothesized to be the trigger which causes the immune system to lose its self-
tolerance and thus lead to an autoimmune attack against itself.9 The exact mechanism for how 
this occurs is still uncertain, however. Additionally, the HLA-DRB1 gene and its related pathway 
is the most noteworthy genetic potential for RA influence; it is not the exclusive pathway for 
how RA may arise from a genetic perspective.1 Due to the many factors which perhaps lead to an 
increased vulnerability to the inclination of RA development, the need arises for further 
determination of the mechanisms behind rheumatoid arthritis pathogenicity. Given the many 
questions concerning how an individual may be predisposed or superimposed to RA due to 
environmental agents, as time continues, new environmental factors may play a role in RA. 
Therefore, the recently introduced form of smoking known as e-vapor, “vaping,” may be yet 
another powerful contributor of future RA generation.7,31 
 Vaping is most commonly utilized by adolescents and young adults.7,33 Since the data on 
the longitudinal effects of vaping has yet to be collected beyond a three-year time period, there is 
an imperative need for the long-term detriment vaping may cause- including potentially leading 
to RA, as seen with chronic cigarette smoking.10,33 Therefore, the experimental proposal within 
this thesis focused on not only the potential connection vaping has with triggering RA, but also 
chronic vape exposure and how it effects RA severity, in respect to both the HLA-DRB1 
pathway and HLA-DRB1 knockout mice. There are heaps of future experiments which could be 
performed specifically focusing on the numerous forms of vaping, but first-and-foremost there 
must simply be any form of these experiments performed. Second-hand vaping, analysis of 
alternative pathways for RA expression, and comparisons between the effects of vaping on adults 
versus children are but a few to consider. Experiments on vaping must be performed due to the 
drastic increase in popularity it has amongst youths. In 2018, 1.3 million middle and high school 
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students were vaping, however, just a mere two years later, over 16 million adolescents within 
the United States have tried or consistently vape.7,25 Consequently, the future generation 
perceives vaping as the healthier alternative to cigarette smoking, but the effects of vaping on 
bodily health is largely unknown. Id est, though vaping is seen in a fairly positive light by many, 
it may be as deleterious as CS in terms of its short and long-term health consequences.  
Upon final analysis, rheumatoid arthritis is one of the most common autoimmune 
diseases within the United States, and globally. Though there are many potential contributors to 
an increased susceptibility for inducing RA, two main factors must be highlighted: the effects of 
one’s genetic predisposition, and the environmental factor of cigarette smoke. With the vaping 
industry only continuing to gain appeal amongst adolescents, the question is raised as to if, and 
how e-vapor potentially contributes to the onset of rheumatoid arthritis as these individuals reach 
late adulthood. Without studies which focus on this potential connection to RA pathogenicity, 
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Supplemental Data  
Supplemental Data 1: Example of a microarray. This particular example of a microarray 
depicts the comparison of osteoarthritis (OA) and rheumatoid arthritis (RA). The original 
caption is included to provide context for the significance of this example. Note the RA 
specific genes (highlighted in yellow) in both a and b. Experimentation similar to this was 
performed in the “Experimental Proposal” portion of this paper. 
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Supplemental Data 2: Established by the European League Against Rheumatism (EULAR), this is the 
recommended pathway to treatment options for rheumatoid arthritis (RA) and its management. Broken 




Supplemental Data 3: Mode of Vape Utilized for Experimental Proposal. SMOK RPM80 is considered a 
median level vape device due to its 0.4-ohm system, customizable temperature gauge and display screen. 
Additionally, this model is not as industrial as other models due to its moderate puff capacity.41 
